Vifor Pharma is having another go at securing EU marketing approval for avacopan, its investigational treatment for ANCA-associated vasculitis, a group of rare kidney autoimmune diseases that lead to significant morbidity and mortality.
The Swiss company pulled its original application for a conditional marketing authorization (CMA) for avacopan nearly two years ago. It...








